Is precision psychiatry possible?
Anyone who has taken a psychiatric medication knows that the status quo in prescribing is a trial and error approach, with patients often cycling through an array of drugs to find the one t
Newsletters and Deep Dive digital magazine
Anyone who has taken a psychiatric medication knows that the status quo in prescribing is a trial and error approach, with patients often cycling through an array of drugs to find the one t
The Home of Accelerating Microbial-Based Drug Development
The recent acquisition of ImmunoGen by AbbVie, which followed the earlier acquisition of Seagen by Pfizer, has brought renewed attention to antibody-drug conjugates (ADCs), highlighting the
Endeavor BioMedicines has completed a third round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
Roche chief executive Thomas Schinecker said today that one in five of the pharma division’s pipel
Editor's Picks
Newsletters and Deep Dive
digital magazine